RxDoctor Payments Data

Hussam Hawamdeh, MD

Interventional Cardiology · Fort Smith, ARNPI 1326455841

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (52.1%), food and beverage and education — rather than concentrated in one kind of arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.3%.

$15,518in general payments, 2019–2025

Across 137 payments — averaging $113.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$3K
  • Abbott$3K
  • Philips North America LLC$2K
  • Medtronic$2K
  • Abiomed$2K
  • GE HealthCare$2K
  • plus $2K from 15 others

What the payments were for

  • Travel & lodging$8,08852%
  • Food & beverage$7,17146%
  • Education$2592%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,518 in reported general payments places this provider in the 75th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$195,337
Medicare patients
1,232
Services billed
3,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$106,293
XareltoRivaroxaban42$39,544
BrilintaTicagrelor21$9,132
ClopidogrelClopidogrel Bisulfate211$1,667
Metoprolol Succinate140$1,228
Atorvastatin Calcium145$1,099
Carvedilol186$972
Amlodipine Besylate203$954
Ranolazine ErRanolazine21$916
Ezetimibe31$795
Diltiazem 24hr Er (Cd)Diltiazem Hcl20$651
Isosorbide Dinitrate15$591
Bumetanide19$562
Amiodarone Hcl36$500
Losartan Potassium86$499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$106,293141 claims
Johnson & JohnsonXarelto$37$39,54442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →